검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Albumin-Bound Paclitaxel /nab-Paclitaxel (Albumin-Bound Paclitaxel /nab-Paclitaxel) Cancer Institute and Hospital, Chi…·High-grade Serous Ovarian Cancer (… ORR 79.5% |
|---|---|
Overview Program | Albumin-Bound Paclitaxel /nab-Paclitaxel |
Overview Company | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Overview Modality | ANTIBODY |
Overview Target | High-grade Serous Ovarian Cancer (HGSOC) |
Overview Indication | High-grade Serous Ovarian Cancer (HGSOC); Fallopian Tube Cancers |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat, In vitro |
Toxicology Major finding | pneumonitis was observed six months after the end of the study |
Clinical Primary efficacy | ORR 79.5% |
Clinical ORR | 79.5% |
Clinical PFS | 20.67 |
Clinical OS | 65.31 |
Clinical Result source | ClinicalTrials.gov NCT01572038 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Albumin-Bound Paclitaxel /nab-Paclitaxel (Albumin-Bound Paclitaxel /nab-Paclitaxel) Cancer Institute and Hospital, Chi…·High-grade Serous Ovarian Cancer (… ORR 79.5% |
|---|---|
Overview Program | Albumin-Bound Paclitaxel /nab-Paclitaxel |
Overview Company | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Overview Modality | ANTIBODY |
Overview Target | High-grade Serous Ovarian Cancer (HGSOC) |
Overview Indication | High-grade Serous Ovarian Cancer (HGSOC); Fallopian Tube Cancers |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat, In vitro |
Toxicology Major finding | pneumonitis was observed six months after the end of the study |
Clinical Primary efficacy | ORR 79.5% |
Clinical ORR | 79.5% |
Clinical PFS | 20.67 |
Clinical OS | 65.31 |
Clinical Result source | ClinicalTrials.gov NCT01572038 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교